Active Filter(s):
Details:
Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Helsinn Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 28, 2022
Details:
Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other CIS countries.
Lead Product(s): Cenegermin
Therapeutic Area: Ophthalmology Product Name: Oxervate
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Dompe Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 26, 2020